Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening: HEPATOLOGY

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 8, 2010, Pages 1426-1434

  Tseng, Po Lin ^a   Wang, Jing Houng ^a   Tung, Hung Da ^a,b   Hung, Chao Hung ^a   Kee, Kwong Ming ^a   Chen, Chien Hung ^a   Chang, Kuo Chin ^a   Lee, Chuan Mo ^a   Changchien, Chi Sin ^a   Chen, Pao Fei ^a   Tsai, Lin San ^c   Lu, Sheng Nan ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c DEPARTMENT OF HEALTH   (Taiwan)

Author keywords

advanced age; Barcelona Clinic Liver Cancer stage; community screening; curative treatment; hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN;

AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT REFUSAL; TUMOR VOLUME;

EID: 77954897962     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06285.x     Document Type: Article

References (48)

1. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004 127 : S159 66.
2. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004 127 : S108 12.
3. Okita K. Clinical aspects of hepatocellular carcinoma in Japan. Int. Med. 2006 45 : 229 233.
4. Lu SN, Wang JH, Liu SL et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006 107 : 2212 2222.
5. Lu SN, Wang JH, Chen PF et al. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol. Biomarkers Prev. 2008 17 : 1813 1821.
6. Chen TH, Chen CJ, Yen MF et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int. J. Cancer 2002 98 : 257 261.
7. Oka H, Kurioka N, Kim K et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990 12 : 680 687.
8. McMahon BJ, Bulkow L, Harpster A et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000 32 : 842 846.
9. Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl. 2000 6 : 320 325.
10. Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001 48 : 251 259.
11. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004 130 : 417 422.
12. Chen JG, Parkin DM, Chen QG et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J. Med. Screen. 2003 10 : 204 209.
13. Yanaga K, Kanematsu T, Takenaka K, Matsumata T, Yoshida Y, Sugimachi K. Hepatic resection for hepatocellular carcinoma in elderly patients. Am. J. Surg. 1988 155 : 238 241.
14. Poon RT, Fan ST, Lo CM et al. Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am. J. Gastroenterol. 1999 94 : 2460 2466.
15. Nomura F, Ohnishi K, Honda M, Satomura Y, Nakai T, Okuda K. Clinical features of hepatocellular carcinoma in the elderly: a study of 91 patients older than 70 years. Br. J. Cancer 1994 70 : 690 693.
16. Hazama H, Omagari K, Matsuo I et al. Clinical features and treatment of hepatocellular carcinoma in eight patients older than eighty years of age. Hepatogastroenterology 2001 48 : 1692 1696.
17. Dohmen K, Shirahama M, Shigematsu H, Irie K, Ishibashi H. Optimal treatment strategy for elderly patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2004 19 : 859 865.
18. Wu CC, Cheng SB, Ho WM, Chen JT, Liu TJ, P'Eng FK. Liver resection for hepatocellular carcinoma in patients with cirrhosis. Br. J. Surg. 2005 92 : 348 355.
19. Collier JD, Curless R, Bassendine MF, James OF. Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. Age Ageing 1994 23 : 22 7.
20. Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004 126 : 1005 1014.
21. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003 362 : 1907 1917.
22. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003 37 : 429 442.
23. Wang JH, Changchien CS, Hu TH et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - survival analysis of 3892 patients. Eur. J. Cancer 2008 44 : 1000 1006.
24. Tsai MC, Kee KM, Chen YD et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J. Gastroenterol. Hepatol. 2007 22 : 92 8.
25. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001 35 : 421 430.
26. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
27. Castells A, Bruix J, Bru C et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993 18 : 1121 1126.
28. Yamamoto J, Okada S, Shimada K et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001 34 : 707 713.
29. Daniele B, De Sio I, Izzo F et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J. Clin. Gastroenterol. 2003 36 : 63 7.
30. Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur. Radiol. 2001 11 : 914 921.
31. Lencioni R, Cioni D, Crocetti L et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005 234 : 961 967.
32. Lee NH, Chau GY, Lui WY, King KL, Tsay SH, Wu CW. Surgical treatment and outcome in patients with a hepatocellular carcinoma greater than 10 cm in diameter. Br. J. Surg. 1998 85 : 1654 1657.
33. Pawlik TM, Poon RT, Abdalla EK et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch. Surg. 2005 140 : 450 457 discussion 7-8.
34. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007 72 (Suppl. 1 2 15.
35. Lu SN, Su WW, Yang SS et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int. J. Cancer 2006 119 : 1946 1952.
36. Teratani T, Ishikawa T, Shiratori Y et al. Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy. Cancer 2002 95 : 816 823.
37. Pignata S, Gallo C, Daniele B et al. Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). Crit. Rev. Oncol. Hematol. 2006 59 : 243 249.
38. Hoshida Y, Ikeda K, Kobayashi M et al. Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis. J. Hepatol. 1999 31 : 860 866.
39. Kaneko K, Shirai Y, Wakai T, Yokoyama N, Akazawa K, Hatakeyama K. Low preoperative platelet counts predict a high mortality after partial hepatectomy in patients with hepatocellular carcinoma. World J. Gastroenterol. 2005 11 : 5888 5892.
40. Camma C, Di Marco V, Orlando A et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J. Hepatol. 2005 42 : 535 540.
41. Pompili M, Rapaccini GL, Covino M et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001 92 : 126 135.
42. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. New Engl. J. Med. 2004 351 : 1521 1531.
43. Lin SM, Yu ML, Lee CM et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J. Hepatol. 2007 46 : 45 52.
44. Yu ML, Lin SM, Chuang WL et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir. Ther. 2006 11 : 985 994.
45. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int. J. Cancer 2004 112 : 44 50.
46. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998 28 : 751 755.
47. Choi D, Lim HK, Rhim H et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur. Radiol. 2007 17 : 684 692.
48. Reichman TW, Bahramipour P, Barone A et al. Hepatitis status, child-Pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. J. Gastrointest. Surg. 2005 9 : 638 645.